The clinical pharmacology of human recombinant erythropoietin (epoetin) was studied in
order to compare the effectiveness of various routes and dosing schedules in dialysis patients. …

To assess the safety, pharmacokinetics, and erythropoietic responses to human recombinant
erythropoietin (epoetin beta), single intravenous doses (10, 50, 150, and 500 IU/kg) were …

Amiodarone has been reported to cause asymptomatic increases in liver function tests in 15
— 55% of patients. Clinically apparent, symptomatic hepatic disease occurs less frequently, …

Adverse cardiac and pulmonary events are frequently observed during hemodialysis and
contribute to significant morbidity and mortality. The temporal relationship between these …

The chemistry, pharmacology, pharmacokinetics, clinical uses and efficacy, adverse effects,
drug interactions, dosage and administration, and formulary considerations of epoetin are …

The metabolic fate of erythropoietin (EPO) remains unknown. Urinary excretion does not
appear to play a major role and liver catabolism has been shown to occur only after terminal …

… Flaharty … Flaharty also served as a consultant to Helsinn and had input with regards to
pharmacokinetic interpretation and assisted in writing the manuscript. … Flaharty …

The effects of probenecid on the pharmacokinetics of 2',3'-dideoxyinosine (ddl) and on the
distribution of ddl to cerebrospinal fluid (CSF) and brain tissue were determined in rats during …

Recombinant human erythropoietin reverses the severe anemia associated with end‐stage
renal disease. Mean half‐life values after a single intravenous bolus dose range from 4–13 …

Although renal wasting of phosphate is relatively common, Fanconi's syndrome following
ifosfamide chemotherapy is rare. This case illustrates the possibility of developing Fanconi's …